proguanil drug combination atovaquone (malarone)

01/01/2018 - "We evaluated existing data on the prophylactic efficacy of atovaquone-proguanil (AP) in order to determine whether prophylaxis in travellers can be discontinued on the day of return from a malaria-endemic area instead of seven days after return as per currently recommended post-travel schedule. "
09/01/2003 - "Atovaquone-proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria."
07/01/2004 - "Malarone appears to be an effective, safe and acceptable oral treatment for uncomplicated malaria."
06/15/2004 - "Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. "
08/15/2002 - "Atovaquone/proguanil is effective in treating acute uncomplicated malaria caused by multiresistant strains of Plasmodium falciparum."

12/01/2003 - "Atovaquone/proguanil was found to be highly effective and safe for the treatment of Plasmodium falciparum malaria in infants and young children weighing 5-10 kg in Africa."
01/01/2018 - "Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers. "
09/01/2005 - "To investigate the pharmacokinetics, safety and efficacy of the recommended 3-day treatment regimen of Malarone in third-trimester pregnant women with acute uncomplicated falciparum malaria. "
01/01/2021 - "Atovaquone-proguanil was effective against uncomplicated P falciparum malaria, although in some instances treatment failure rates were between 5% and 10%. "
01/01/2002 - "Based on our experience, Malarone appears to be effective, well-tolerated, and suitable for routine management of uncomplicated imported Plasmodium falciparum malaria."

10/01/2023 - "A suspected diagnosis of Plasmodium knowlesi infection was confirmed by PCR, and treatment with atovaquone/proguanil brought successful recovery. "
09/01/2022 - "A second treatment with atovaquone-proguanil was successful in eliminating the infection, with no further relapses. "
10/05/2021 - "All participants received atovaquone/proguanil treatment if blood-stage infection was detected or on day 29. "
09/01/2020 - "Atovaquone-proguanil treatment failure in a case of pediatric Plasmodium falciparum infection: Malabsorption and resistance."
11/01/2018 - "We show that daily administration of atovaquone-proguanil (ATQ-PG; ATQ, 30 mg/kg, and PG, 10 mg/kg) protects 5 of 5 mice from liver stage infection, consistent with the use in humans as a causal prophylactic drug. "

09/01/2012 - "A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. "
10/01/2002 - "Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia."
11/01/2006 - "Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis."
01/01/2018 - "Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options."
11/01/2002 - "Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity."

12/15/2007 - "Low-level parasitemia recurred 20 weeks later and was eradicated by administration of atovaquone-proguanil monotherapy. "
05/01/1999 - "Recurrent parasitemia occurred within 28 days in 0 of 99 subjects who subsequently received prophylaxis with atovaquone/proguanil and 1 of 81 subjects who subsequently received placebo. "
12/15/2007 - "Finally, red blood cell exchange transfusion, anti-Babesia therapy, and the addition of atovaquone-proguanil to the treatment regimen led to symptomatic improvement and elimination of parasitemia. "
09/01/2014 - "In all dogs except one treated with Malarone(®), parasitemia decreased, and anemia improved soon after initiation of treatment. "
04/01/1999 - "Adult volunteers received a three-day treatment course of Malarone to eliminate pre-existing parasitemia and were then immediately randomized to treatment with either one Malarone tablet daily (n = 136), or one placebo tablet daily (n = 138) for at least 10 weeks. "